Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)
Detection Principle
ImmunoAssay-Antibody
Target
IgG (Abbott), IgG/IgA (Euroimmun), IgG-IgM (NG Biotech)
Testing Method Category
Testing Method
kits
Testing Method - Additional Info
ELISA (Euroimmun), CLIA(Abbott), LFIA(NG Biotech)
Reported Performance
Sensitivity: 100% (IgG overall, >15 dpo); Specificity: 98% (IgG CLIA and LFIA), 95.8% (IgG ELISA), 78.9% (IgA ELISA), 95.8% (IgM LFIA)
Sample Size
293 samples
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements